Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 350 Polycystic Ovary Syndrome 39 Endometrial Neoplasms 22 Neoplasm Metastasis 21 Ovarian Neoplasms 16 Infertility 12 Neoplasms 11 Fallopian Tube Neoplasms 8 Advanced Breast Cancer 8 Triple Negative Breast Neoplasms 7 Carcinoma, Intraductal, Noninfiltrating 7 Carcinoma, Ductal, Breast 7 Breast Neoplasms, Male 7 Recurrence 6 Osteoporosis 6 Carcinoma, Lobular 6 Breast Diseases 6 Breast Carcinoma In Situ 6 Prostatic Neoplasms 5 Leiomyoma 4 Infertility, Female 4 Hereditary Sensory and Autonomic Neuropathies 4 Breast Cancer Metastatic 4 Neoplasms, Hormone-Dependent 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Non-Small-Cell Lung 3 Anovulation 3 Uterine Neoplasms 2 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2

Interventions

ribociclib 1 Tretinoin 1 Letrozole 1 Goserelin 1 Drug Therapy 1 Chemotherapy, Adjuvant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HER2 Negative Breast Cancer × Letrozole × Clear all

NCT06953882 2026-05-26

SELECT

Yale University

Phase 2 Recruiting

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡